Institute Sainte Catherine ISC

Avignon, France

Institute Sainte Catherine ISC

Avignon, France
SEARCH FILTERS
Time filter
Source Type

Cretel-Durand E.,Unit of Transversal Onco Geriatry UTOG | Nouguerede E.,Unit of Transversal Onco Geriatry UTOG | Nouguerede E.,Aix - Marseille University | Le Caer H.,CH Saint Brieuc Hopital Ives Le Foll | And 25 more authors.
Trials | Year: 2017

Background: Cancer incidence and social isolation increase along with advanced age, and social isolation potentiates the relative risk of death by cancer. Once spotted, social isolation can be averted with the intervention of a multidisciplinary team. Techniques of automation and remote assistance have already demonstrated their positive impact on falls prevention and quality of life (QoL), though little is known about their impact on socially isolated elderly patients supported for cancer. The primary objective of the PREDOMOS study is to evaluate the impact of establishing a Program of Social intervention associated with techniques of Domotic and Remote assistance (PS-DR) on the improvement of QoL of elderly isolated patients, treated for locally advanced or metastatic cancer. The secondary objectives include treatment failure, tolerance, survival, and autonomy. Methods/design: This trial is a multicenter, prospective, randomized, placebo-controlled, open-label, two-parallel group study. The setting is 10 French oncogeriatric centers. Inclusion criteria are patients aged at least 70years with a social isolation risk and a histological diagnosis of cancer, locally advanced or metastatic disease. The groups are (1) the control group, receiving usual care; (2) the experimental group, receiving usual care associating with monthly social assistance, domotic, and remote assistance. Participants are randomized in a 1:1 allocation ratio. Evaluation times involve inclusion (randomization) and follow-up (12months). The primary endpoint is QoL at 3months (via European Organization for Research and Treatment of Cancer (EORTC) QLQ C30); secondary endpoints are social isolation, time to treatment failure, toxicity, dose response-intensity, survival, autonomy, and QoL at 6months. For the sample size, 320 individuals are required to obtain 90% power to detect a 10-point difference (standard deviation 25) in QoL score between the two groups (20% loss to follow-up patients expected). Discussion: The randomized controlled design is the most appropriate design to demonstrate the efficacy of a new experimental strategy (Evidence-Based Medicine Working Group classification). National and international recommendations could be updated based on the findings of this study. Trial registration: ClinicalTrials.gov, NCT02829762. Registered on 29 June 2016. © 2017 The Author(s).

Loading Institute Sainte Catherine ISC collaborators
Loading Institute Sainte Catherine ISC collaborators